The global sleeping pills market size was valued at USD 91.17 billion in 2025 and is projected to grow from USD 96.18 billion in 2026 to USD 147.61 billion by 2034, registering a CAGR of 5.5% during the forecast period from 2026 to 2034. North America dominated the sleeping pills market with a market share of 39.6% in 2025.
Sleeping pills are medications designed to help individuals fall asleep, stay asleep, or improve overall sleep quality by affecting brain chemicals that regulate the sleep–wake cycle. They are available in prescription and over-the-counter forms, depending on the formulation and intended use. These medications are commonly used for the short-term management of insomnia and other sleep disturbances. Proper use under medical guidance is important to minimize the risk of side effects, dependence, and reduced effectiveness with prolonged use.
Download a Free Sample To learn more about this report,
Shift Toward Orexin-Based and More Targeted Insomnia Therapies
The sleeping pills market is shifting toward therapies that target specific sleep-regulation pathways rather than relying mainly on traditional sedative mechanisms. Dual orexin receptor antagonists (DORAs) are gaining attention because they act on the orexin system involved in wakefulness and sleep regulation. This is changing the competitive focus toward medicines that aim to improve sleep while addressing concerns associated with conventional hypnotics. As clinical evidence and regulatory experience expand, DORA therapies are becoming an increasingly important part of the sleeping pills market growth.
For instance, in January 2025, Idorsia reported continued development of daridorexant through studies covering insomnia associated with conditions such as psychiatric and neurological disorders, menopause-related symptoms, and sleep apnea. The company also reported that daridorexant was available in multiple European and North American markets, supporting the broader development of orexin-based insomnia treatment.
Increasing Use of Combination and Digital Approaches for Insomnia Management
Insomnia management is increasingly moving beyond medication alone toward treatment models that combine pharmacological therapy with behavioral interventions. Digital CBT-I, telehealth services, and software-based sleep programs can improve access to behavioral treatment and support patients alongside prescription medicines. This shift is influencing the sleeping pills market because medication providers increasingly operate within broader insomnia-care pathways rather than standalone drug treatment.
For instance, in June 2025, the American Academy of Sleep Medicine released a public-comment draft guideline focused specifically on combining pharmacological treatment with behavioral-psychological treatment for chronic insomnia. The guideline addresses concurrent use of hypnotic medicines and interventions such as CBT-I, reflecting growing clinical interest in integrated treatment models.
Growing Recognition of Insomnia as a Common Clinical Condition
The sleeping pills market is supported by greater recognition of insomnia as a clinically important disorder requiring appropriate diagnosis and treatment. More standardized assessment can identify patients who may benefit from pharmacological or behavioral interventions, expanding the addressable treatment population. Recent research also provides stronger evidence about the scale of the underlying condition, supporting continued demand for insomnia management.
For instance, in May 2025, a meta-analysis published in the Journal of Sleep Research reviewed 47 studies and estimated the prevalence of insomnia disorder at 12.4% when standardized diagnostic interviews were used. The findings also highlighted the importance of consistent assessment methods for identifying insomnia.
Safety Concerns Continue to Limit Long-Term Use of Hypnotic Medicines
Safety considerations remain a major restraint because some sleeping medicines can cause adverse effects that influence prescribing decisions and patient adherence. Concerns around sedation, dizziness, dependence, misuse, and other adverse reactions can encourage physicians to carefully evaluate treatment duration and alternatives. These issues can limit sustained use even when medications provide effective short-term symptom relief.
For instance, in July 2025, a systematic review and network meta-analysis assessed adverse events associated with pharmacological treatments for insomnia in adults. The analysis found associations between several commonly used insomnia medicines and nervous-system or gastrointestinal adverse events, reinforcing the need to balance treatment benefits with safety considerations.
Expansion of Personalized Insomnia Treatment Based on Patient Characteristics
Advances in insomnia research are creating opportunities for more individualized treatment strategies based on patient characteristics, comorbidities, symptom patterns, and treatment response. Better differentiation among insomnia subtypes can help clinicians select therapies more appropriately and may support the development of medicines designed for specific patient populations. This creates opportunities for pharmaceutical companies to expand beyond broad insomnia indications toward more targeted treatment approaches.
For instance, in February 2025, researchers published findings in The Lancet examining different insomnia symptom profiles and their associations with health outcomes, reinforcing the potential value of distinguishing clinically meaningful patient characteristics when evaluating insomnia.
Maintaining Treatment Adherence Over Extended Insomnia Management
Insomnia often requires ongoing management, creating challenges in maintaining patient adherence to prescribed treatment plans. Patients may discontinue medicines because of perceived lack of effectiveness, adverse effects, changing sleep patterns, or preferences for non-drug approaches. Manufacturers and healthcare providers therefore need to support treatment continuity while ensuring that therapy remains appropriate as patients' sleep conditions change.
For instance, in January 2025, a European expert consensus on switching or deprescribing hypnotic medicines for chronic insomnia was published, highlighting the need for structured treatment transitions and ongoing clinical management rather than relying on uninterrupted long-term use of a single sleeping medicine.
Non-Benzodiazepines Dominated the Market with 56.2% Share in 2025
The non-benzodiazepines segment accounted for the largest share of the global sleeping pills market at 56.2% in 2025, driven by their improved safety profile, lower risk of dependence compared to traditional benzodiazepines, and widespread use in the treatment of insomnia and other sleep-related disorders.
Request Customizationto receive a tailored report.
Long-term Use is Projected to Register the Fastest Growth at a CAGR of 6.35%
The long-term use segment is expected to grow at the highest CAGR of 6.35% during 2026–2034, supported by the rising prevalence of chronic insomnia, increasing awareness of sleep disorders, expanding access to prescription therapies, and ongoing monitoring of patients requiring prolonged treatment.
Insomnia Dominated the Market with 54.9% Share in 2025
The insomnia segment held the largest share of the global sleeping pills market at 54.9% in 2025, owing to the growing incidence of stress-related sleep disturbances, changing lifestyles, increasing mental health concerns, and the high demand for pharmacological treatments that improve sleep quality and duration.
Online Pharmacies are Projected to Register the Fastest Growth at a CAGR of 7.28%
The online pharmacies segment is anticipated to witness the fastest growth at a CAGR of 7.28% during the forecast period, driven by increasing digital healthcare adoption, convenient home delivery services, competitive pricing, and rising consumer preference for online purchasing of prescription and over-the-counter sleep medications.
Speak to an Analystto discuss market opportunities.
North America dominated the Sleeping Pills market, accounting for 39.6% of the market and reaching USD 36.1 billion in 2025. The region benefits from a high prevalence of insomnia and sleep disorders, advanced healthcare infrastructure, increasing mental health awareness, and strong access to prescription and over-the-counter sleep medications. Growing adoption of digital healthcare services and ongoing pharmaceutical innovation continue to support market expansion.
The United States accounted for an estimated USD 31.41 billion in 2025, representing the largest share of the North American market. Rising cases of chronic insomnia, increasing stress-related sleep disorders, an aging population, and the availability of advanced prescription therapies continue to drive market growth.
Canada generated an estimated USD 4.69 billion in 2025. The market is supported by increasing awareness of sleep health, expanding access to healthcare services, and growing demand for effective pharmacological treatments for insomnia and related disorders.
Unlock Regional Insightsto access country-level data, & regional trends.
Europe accounted for 28.4% of the market, reaching USD 25.89 billion in 2025. The regional market is driven by rising prevalence of sleep disorders, favorable healthcare reimbursement systems, increasing elderly populations, and growing demand for advanced sleep therapies. Continuous pharmaceutical innovation and expanding mental healthcare services further support market growth.
Germany led the European market with an estimated value of USD 6.99 billion in 2025. The country's advanced healthcare infrastructure, high healthcare expenditure, and increasing diagnosis of sleep disorders continue to drive demand for sleeping medications.
The United Kingdom accounted for an estimated USD 5.70 billion in 2025. Growing awareness of insomnia management, increasing mental health initiatives, and greater access to prescription sleep therapies are supporting market expansion.
Asia-Pacific accounted for 21.7% of the market, valued at USD 19.78 billion in 2025, and is projected to witness strong growth at a CAGR of 6.31% during the forecast period. Rapid urbanization, changing lifestyles, increasing stress levels, rising healthcare expenditure, and improved diagnosis of sleep disorders are accelerating market development across the region.
China accounted for an estimated USD 11.47 billion in 2025, making it the largest market in Asia-Pacific. Rising healthcare investments, increasing awareness of sleep disorders, expanding pharmaceutical access, and a growing elderly population continue to support market growth.
Japan generated an estimated USD 3.56 billion in 2025. The country's aging population, high prevalence of insomnia, and advanced healthcare system continue to contribute to steady market expansion.
The Middle East and Africa represented 4.2% of the market, totaling USD 3.83 billion in 2025. Increasing healthcare investments, growing awareness of sleep disorders, and improving access to pharmaceutical treatments are contributing to regional market growth. Expanding healthcare infrastructure is expected to create additional opportunities during the forecast period.
The United Arab Emirates accounted for an estimated USD 0.84 billion in 2025. Rising healthcare modernization initiatives, increasing diagnosis of sleep disorders, and growing demand for advanced therapeutic solutions continue to support market growth.
Africa generated an estimated USD 2.99 billion in 2025. The market is gradually expanding due to improving healthcare access, rising awareness of sleep-related disorders, and increasing availability of pharmaceutical treatments.
Latin America accounted for 6.1% of the market, valued at USD 5.56 billion in 2025. Growing healthcare expenditure, increasing prevalence of insomnia, and rising awareness of sleep health are supporting regional market growth. Expanding pharmaceutical distribution networks and improved healthcare access are further driving market expansion.
Brazil accounted for an estimated USD 2.39 billion in 2025, making it the largest market in Latin America. Increasing diagnosis of sleep disorders, expanding healthcare services, and growing pharmaceutical adoption continue to support market growth.
Mexico generated an estimated USD 1.56 billion in 2025. Rising healthcare investments, growing awareness of sleep disorders, and increasing availability of prescription and over-the-counter sleep medications are driving market expansion.
Customize This Report to Match Your Strategic Objectives
Author's Details
Senior Research Associate
Dhanshee Bhapkar is a healthcare research professional with 4+ years of experience in market intelligence, specializing in market analysis, secondary research, market estimation, and forecasting across the pharmaceutical, biopharmaceutical, and medical device sectors. She provides actionable insights into market dynamics, competitive intelligence, industry trends, and growth opportunities to support strategic business decision-making.
Her expertise includes assessing market size, growth potential, and revenue opportunities through structured market estimation and forecasting methodologies, including top-down, bottom-up, and epidemiology (EPI)-based approaches. She has hands-on experience analyzing disease epidemiology, treatment landscapes, market trends, competitive scenarios, and industry developments to develop robust market forecasts.
Insulin Market Size, Share, Growth, Analysis, Report, 2034
Short-Acting Insulin Market Size, Share, Growth, Analysis, 2034
Varicose Vein Treatment Market Size, Share, Growth, Analysis, 2034
Oncology Drugs Market Size, Share, Growth, Analysis, Report, 2034
Legalized Cannabis Market Size, Share, Growth, Analysis, 2034
Immunotherapy Drugs Market Size, Share, Growth, 2034
We are featured on:
sales@straitsresearch.com